LP-2307

DB17470ExperimentalVaccines

LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

Code names
LP-2307

Which companies are running trials of LP-2307, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account